Press release: Uppsala, August 21, 2019. Dicot AB (publ), developer of drugs targeting sexual dysfunction, today announced that Göran Beijer, CEO, will participate and host one-on-one investor meetings at the following upcoming investor conferences: BioStock Live Capital Markets Day and the LSX Nordic Congress 2019.
Event Details:
BioStock Live Capital Markets Day
Tuesday, August 27, 2019
Presentation at 10:00 AM CET
A live webcast of the presentation can be accesed via the following link: https://www.eventbrite.com/e/biostock-live-sthlm-august-27-biljetter-68783139221
LSX Nordic Congress 2019
Thursday, August 29, 2019
Hosting Investor Meetings
Göran Beijer will be representing the company and hosting one-on-one meetings during the conference. To schedule a meeting please contact the LSX Nordic Congress organizers or Gabriela Urquilla at Gabriela.Urquilla@dicot.se.
For more information, please contact:
Julie Silber
CFO/Investor Relations Director, Dicot
Tel.: +46-79-3486277
Email: julie.silber@dicot.se
About Dicot AB (publ)
Dicot"s business concept is to develop the product LibiguinTM as a drug for the treatment of sexual dysfunctions. The development takes place in-house up to clinical phases. It is the company"s intention to subsequently enter into strategic alliances at appropriate times, or alternatively conduct a trade sale, with established major pharmaceutical companies to be able to introduce LibiguinTM on the world market. Dicot is listed on the Spotlight Stock Market and has approximately 700 shareholders. www.dicot.se